{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-24-007203","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.429719+00:00","generated_at":"2026-05-30T00:43:12.603655+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"VolitionRx Q3 revenue $475K, up 187% YoY; sold >110K Nu.Q Vet tests in 9 months","bullets":["Q3 2024 revenue $475K, up 187% YoY; YTD revenue $1M, up 96%.","Nu.Q Vet revenue up 307% in Q3; >110,000 tests sold in first 9 months of 2024.","Cash used in operations $5.4M in Q3, down 36% YoY; cash balance $5.4M at Sept 30.","Received >$2.2M in non-dilutive funding commitment from Walloon Region post-quarter.","Reaffirms goal to be cash neutral (income matching expenditure) in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-24-007203","json":"https://secwatch.observer/filing/0001477932-24-007203.json","markdown":"https://secwatch.observer/filing/0001477932-24-007203.md","text":"https://secwatch.observer/filing/0001477932-24-007203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793224007203/0001477932-24-007203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793224007203/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:43:12.603655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}